The use of methotrexate in rheumatoid arthritis. Recommendations of the All-Russian public organization “Association of Rheumatologists of Russia”

Rheumatoid arthritis (RA) is the most frequent immunoinflammatory (autoimmune) rheumatic disease characterized by chronic erosive arthritis and systemic damage to internal organs. The data obtained in the course of basic research on deciphering the mechanisms of action of methotrexate (MT) and the materials of numerous randomized placebocontrolled trials, observational studies and national registries have strengthened the position of MT as the “gold standard” of RA pharmacotherapy and a key component of the “Treatment to Target” strategy. This was the basis for the development of new recommendations of the Association of Rheumatologists of Russia (ARR) concerning the use of MT in RA, according to which MT is considered as the drug of “choice” for induction and maintenance of remission in patients with early and advanced RA, including those who need combination therapy of MT with glucocorticoids, standard Disease-Modifying Antirheumatic Drugs (DMARDs), biologics and targeted synthetic DMARDs. Special attention is paid to the safety of MT therapy and the impact of MT on comorbid pathology associated with cardiovascular complications and interstitial lung disease. Implementation of the ARR recommendations into clinical practice will reduce the risk of disability and improve life prognosis in patients with RA.

1. Smolen JS, Aletaha D, Barton A, Burmester GR, Emery P, Firestein GS, et al. Rheumatoid arthritis. Nat Rev Dis Primers. 2018;4:18001. doi: 10.1038/nrdp.2018.1

2. Gravallese EM, Firestein GS. Rheumatoid arthritis – Common origins, divergent mechanisms. N Engl J Med. 2023;388(6):529-542. doi: 10.1056/NEJMra2103726

3. Насонов ЕЛ. Фармакотерапия ревматоидного артрита: новая стратегия, новые мишени. Научно-практическая ревматология. 2017;55(4):409-419. [Nasonov EL. Pharmacotherapy for rheumatoid arthritis: New strategy, new targets. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2017;55(4):409-419 (In Russ.)]. doi: 10.14412/1995-4484-2017-409-419

4. Baker KF, Isaacs JD. Novel therapies for immune-mediated inflammatory diseases: What can we learn from their use in rheumatoid arthritis, spondyloarthritis, systemic lupus erythematosus, psoriasis, Crohn’s disease and ulcerative colitis? Ann Rheum Dis. 2018;77(2):175-187. doi: 10.1136/annrheumdis-2017-211555

5. Smolen JS, Aletaha D, Bijlsma JW, Breedveld FC, Boumpas D, Burmester G, et al.; T2T Expert Committee. Treating rheumatoid arthrit is to target: recommendations of an international task force. Ann Rheum Dis. 2010;69(4):631-637. doi: 10.1136/ard.2009.123919

6. Smolen JS, Aletaha D. Rheumatoid arthritis therapy reappraisal: Straregies, opportunities and challenges. Nat Rev Rheumatol. 2015;11(5):276-289. doi: 10.1038/nrrheum.2015.8

7. Smolen JS, Landewé RBM, Bergstra SA, Kerschbaumer A, Sepriano A, Aletaha D, Caporali R, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023;82(1):3-18. doi: 10.1136/ard-2022-223356

8. Насонов ЕЛ, Каратеев ДЕ, Чичасова НВ. Новые рекомендации по лечению ревматоидного артрита (EULAR, 2013): место метотрексата. Научно-практическая ревматология. 2014;52(1):8-26. [Nasonov EL, Karateev DE, Chichasova NV. New recommendations for the management of rheumatoid arthritis (EULAR, 2013): The role of methotrexate. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2014;52(1):8-26 (In Russ.)] doi: 10.14412/1995-4484-2014-8-26

9. Насонов ЕЛ. Метотрексат при ревматоидном артрите – 2015: новые факты и идеи. Научно-практическая ревматология. 2015;53(4):421-433. [Nasonov EL. Methotrexate in rheumatoid arthritis – 2015: New facts and ideas. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2015;53(4): 421-433 (In Russ.)]. doi: 10.14412/1995-4484-2015-421-433

10. Bedoui Y, Guillot X, Sélambarom J, Guiraud P, Giry C, Jaffar-Bandjee MC, et al. Methotrexate an old drug with new tricks. Int J Mol Sci. 2019;20(20):5023. doi: 10.3390/ijms20205023

11. Lucas CJ, Dimmitt SB, Martin JH. Optimising low-dose methotrexate for rheumatoid arthritis – A review. Br J Clin Pharmacol. 2019;85(10):2228-2234. doi: 10.1111/bcp.14057

12. Taylor PC, Balsa Criado A, Mongey AB, Avouac J, Marotte H, Mueller RB. How to get the most from methotrexate (MTX) treatment for your rheumatoid arthritis patient? – MTX in the treatto-target strategy. J Clin Med. 2019;8(4):515. doi: 10.3390/jcm8040515

13. Giollo A, Fuzzi E, Doria A. Methotrexate in early rheumatoid arthritis: Is the anchor drug still holding? Autoimmun Rev. 2022;21(4):103031. doi: 10.1016/j.autrev.2022.103031

14. Zhao Z, Hua Z, Luo X, Li Y, Yu L, Li M, et al. Application and pharmacological mechanism of methotrexate in rheumatoid arthritis. Biomed Pharmacother. 2022;150:113074. doi: 10.1016/j.biopha.2022.113074

15. Cronstein BN, Aune TM. Methotrexate and its mechanisms of action in inflammatory arthritis. Nat Rev Rheumatol. 2020;16(3): 145-154. doi: 10.1038/s41584-020-0373-9

16. Насонов ЕЛ. Фармакотерапия ревматоидного артрита: российские и международные рекомендации. Научно-практическая ревматология. 2016;54(5):557-571. [Nasonov EL. Pharmacotherapy for rheumatoid arthritis: Russian and international guidelines. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2016;54(5):557-571 (In Russ.)]. doi: 10.14412/1995-4484-2016-557-571

17. Valerio V, Kwok M, Loewen H, Winkler J, Mody GM, Scuccimarri R, et al. Systematic review of recommendations on the use of methotrexate in rheumatoid arthritis. Clin Rheumatol. 2021;40(4):1259-1271. doi: 10.1007/s10067-020-05363-2

18. Mian A, Ibrahim F, Scott DL. A systematic review of guidelines for managing rheumatoid arthritis. BMC Rheumatol. 2019;3:42. doi: 10.1186/s41927-019-0090-7

19. Combe B, Landewe R, Daien CI, Hua C, Aletaha D, Álvaro-Gracia JM, et al. 2016 update of the EULAR recommendations for the management of early arthritis. Ann Rheum Dis. 2017;76(6): 948-959. doi: 10.1136/annrheumdis-2016-210602

20. Smolen JS, Landewé RBM, Bijlsma JWJ, Burmester GR, Dougados M, Kerschbaumer A, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis. 2020;79(6):685-699. doi: 10.1136/annrheumdis-2019-216655

21. Singh JA, Saag KG, Bridges SL Jr, Akl EA, Bannuru RR, Sullivan MC, et al.; American College of Rheumatology. 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken). 2016;68(1):1-25. doi: 10.1002/acr.22783

22. Fraenkel L, Bathon JM, England BR, St Clair EW, Arayssi T, Carandang K, et al. 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken). 2021;73(7):924-939. doi: 10.1002/acr.24596

23. Lau CS, Chia F, Dans L, Harrison A, Hsieh TY, Jain R, et al. 2018 update of the APLAR recommendations for treatment of rheumatoid arthritis. Int J Rheum Dis. 2019;22(3):357-375. doi: 10.1111/1756-185X.13513

24. Katchamart W, Bourré-Tessier J, Donka T, Drouin J, Rohekar G, Bykerk VP, et al.; Canadian 3e Initiative Consensus Group. Canadian recommendations for use of methotrexate in patients with rheumatoid arthritis. J Rheumatol. 2010;37(7):1422-1430. doi: 10.3899/jrheum.090978

25. Bykerk VP, Akhavan P, Hazlewood GS, Schieir O, Dooley A, Haraoui B, et al.; Canadian Rheumatology Association. Canadian Rheumatology Association recommendations for pharmacological management of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs. J Rheumatol. 2012;39(8):1559-1582. doi: 10.3899/jrheum.110207

26. Tornero Molina J, Ballina García FJ, Calvo Alén J, Caracuel Ruiz MÁ, Carbonell Abelló J, López Meseguer A, et al. Recommendations for the use of methotrexate in rheumatoid arthritis: Up and down scaling of the dose and administration routes. Reumatol Clin. 2015;11(1):3-8. doi: 10.1016/j.reuma.2014.02.012

27. Duarte AC, Santos-Faria D, Gonçalves MJ, Sepriano A, Mourão AF, Duarte C, et al. Portuguese recommendations for the use of methotrexate in rheumatic diseases – 2016 update. Acta Reumatol Port. 2017;42(2):127-140.

28. Ledingham J, Gullick N, Irving K, Gorodkin R, Aris M, Burke J, et al.; BSR and BHPR Standards, Guidelines and Audit Working Group. BSR and BHPR guideline for the prescription and monitoring of non-biologic disease-modifying anti-rheumatic drugs. Rheumatology (Oxford). 2017;56(6):865-868. doi: 10.1093/rheumatology/kew479

29. Tornero Molina J, Calvo Alen J, Ballina J, Belmonte MÁ, Blanco FJ, Caracuel MÁ, et al. Recommendations for the use of parenteral methotrexate in rheumatic diseases. Reumatol Clin (Engl Ed). 2018 ;14(3):142-149. doi: 10.1016/j.reuma.2016.12.001

30. Visser K, Katchamart W, Loza E, Martinez-Lopez JA, Salliot C, Trudeau J, et al. Multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatolo gists in the 3E Initiative. Ann Rheum Dis. 2009;68(7):1086-1093. doi: 10.1136/ard.2008.094474

31. Hazlewood GS, Pardo JP, Barnabe C, Schieir O, Barber CEH, Proulx L, et al. Canadian Rheumatology Association living guidelines for the pharmacological management of rheumatoid arthritis with disease-modifying antirheumatic drugs. J Rheumatol. 2022;49(10):1092-1099. doi: 10.3899/jrheum.220209

32. Daien C, Hua C, Gaujoux-Viala C, Cantagrel A, Dubremetz M, Dougados M, et al. Update of French society for rheumatology recommendations for managing rheumatoid arthritis. Joint Bone Spine. 2019;86(2):135-150. doi: 10.1016/j.jbspin.2018.10.002

33. Fiehn C, Holle J, Iking-Konert C, Leipe J, Weseloh C, Frerix M, et al. S2e-Leitlinie: Therapie der rheumatoiden Arthritis mit krankheitsmodifizierenden Medikamenten [S2e guideline: treatment of rheumatoid arthritis with disease-modifying drugs]. Z Rheumatol. 2018;77(Suppl 2):35-53. doi: 10.1007/s00393-018-0481-y

34. Kawahito Y, Morinobu A, Kaneko Y, Kohno M, Hirata S, Kishimoto M, et al. Drug treatment algorithm and recommendations from the 2020 update of the Japan College of Rheumatology clinical practice guidelines for the management of rheumatoid arthritissecondary publication. Mod Rheumatol. 2023;33(1):21-35. doi: 10.1093/mr/roac017

35. Kameda H, Fujii T, Nakajima A, Koike R, Sagawa A, Kanbe K, et al.; Japan College of Rheumatology subcommittee on the guideline for the use of methotrexate in patients with rheumatoid arthritis. Japan College of Rheumatology guideline for the use of methotrexate in patients with rheumatoid arthritis. Mod Rheumatol. 2019;29(1):31-40. doi: 10.1080/14397595.2018.1472358

36. Насонов ЕЛ. Лечение ревматоидного артрита 2012: место метотрексата. Научно-практическая ревматология. 2012;51(Прил):1-24. [Nasonov EL. Treatment of rheumatoid arthritis 2012: Place of methotrexate. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2012;51(Suppl):1-24 (In Russ.)].

37. Насонов ЕЛ, Мазуров ВИ, Каратеев ДЕ Лукина ГВ, Жиляев ЕВ, Амирджанова ВН, и др. Проект рекомендаций по лечению ревматоидного артрита Общероссийской общественной организации «Ассоциация ревматологов России» – 2014 (часть 1). Научно-практическая ревматология. 2014;52(5):477-494. [Nasonov EL, Mazurov VI, Karateev DE, Lukina GV, Zhilyaev EV, Amirdzhanova VN, et al. Project: Recommendations on treatment of rheumatoid arthritis developed by All-Russian Public Organization «Association of Rheumatologists of Russia» – 2014 (Part 1). Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2014;52(5):477-494 (In Russ.)]. doi: 10.14412/1995-4484-2014-477-494

38. Tornero-Molina J, Alperi-López M, Castellví I, de Agustínde Oro JJ, Escudero A, García-Vicuña R, et al. Experts document on methotrexate use in combined therapy with biological or targeted synthetic disease modifying drugs in patients with rheumatoid arthritis. Reumatol Clin (Engl Ed). 2022;18(1):33-41. doi: 10.1016/j.reumae.2020.08.009

39. Tanaka Y. Subcutaneous injection of methotrexate: Advantages in the treatment of rheumatoid arthritis. Mod Rheumatol. 2022:roac156. doi: 10.1093/mr/roac156

40. Bello AE, Perkins EL, Jay R, Efthimiou P. Recommendations for optimizing methotrexate treatment for patients with rheumatoid arthritis. Open Access Rheumatol. 2017;9:67-79. doi: 10.2147/OARRR.S131668

41. Bramley D. What dose of folic acid to use with methotrexate in rheumatoid arthritis? Drug Ther Bull. 2021;59(7):103-106. doi: 10.1136/dtb.2020.000061

42. Duong SQ, Crowson CS, Athreya A, Atkinson EJ, Davis JM 3rd, Warrington KJ, et al. Clinical predictors of response to methotrexate in patients with rheumatoid arthritis: A machine learning approach using clinical trial data. Arthritis Res Ther. 2022;24(1):162. doi: 10.1186/s13075-022-02851-5

43. Rigby WFC, Lampl K, Low JM, Furst DE. Review of routine laboratory monitoring for patients with rheumatoid arthritis receiving biologic or nonbiologic DMARDs. Int J Rheumatol. 2017;2017:9614241. doi: 10.1155/2017/9614241

44. Goodman SM, Springer BD, Chen AF, Davis M, Fernandez DR, Figgie M, et al. 2022 American College of Rheumatology/American Association of Hip and Knee Surgeons guideline for the perioperative management of antirheumatic medication in patients with rheumatic diseases undergoing elective total hip or total knee arthroplasty. Arthritis Rheumatol. 2022;74(9):1464-1473. doi: 10.1002/art.42140

45. Sammaritano LR, Bermas BL, Chakravarty EE, Chambers C, Clowse MEB, Lockshin MD, et al. 2020 American College of Rheumatology guideline for the management of reproductive health in rheumatic and musculoskeletal diseases. Arthritis Rheumatol. 2020;72(4):529-556. doi: 10.1002/art.41191

46. Furer V, Rondaan C, Heijstek MW, Agmon-Levin N, van Assen S, Bijl M, et al. 2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis. 2020;79(1):39-52. doi: 10.1136/annrheumdis-2019-215882

47. Ajeganova S, van Steenbergen HW, van Nies JA, Burgers LE, Huizinga TW, van der Helm-van Mil AH. Disease-modifying antirheumatic drug-free sustained remission in rheumatoid arthritis: An increasingly achievable outcome with subsidence of disease symptoms. Ann Rheum Dis. 2016;75(5):867-873. doi: 10.1136/annrheumdis-2014-207080

48. van Dongen H, van Aken J, Lard LR, Visser K, Ronday HK, Hulsmans HM, et al. Efficacy of methotrexate treatment in patients with probable rheumatoid arthritis: A double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 2007;56(5):1424-1432. doi: 10.1002/art.22525

49. Burgers LE, Allaart CF, Huizinga TWJ, van der Helmvan Mil AHM. Brief report: Clinical trials aiming to prevent rheumatoid arthritis cannot detect prevention without adequate risk stratification: A trial of methotrexate versus placebo in undifferentiated arthritis as an example. Arthritis Rheumatol. 2017;69(5):926-931. doi: 10.1002/art.40062

50. Gerlag DM, Raza K, van Baarsen LG, Brouwer E, Buckley CD, Burmester GR, et al. EULAR recommendations for terminology and research in individuals at risk of rheumatoid arthritis: Report from the Study Group for Risk Factors for Rheumatoid Arthritis. Ann Rheum Dis. 2012;71(5):638-641. doi: 10.1136/annrheumdis-2011-200990

51. Krijbolder DI, Verstappen M, van Dijk BT, Dakkak YJ, Burgers LE, Boer AC, et al. Intervention with methotrexate in patients with arthralgia at risk of rheumatoid arthritis to reduce the development of persistent arthritis and its disease burden (TREAT EARLIER): A randomised, double-blind, placebo-controlled, proof-of-concept trial. Lancet. 2022;400(10348):283-294. doi: 10.1016/S0140-6736(22)01193-X

52. Bujor AM, Janjua S, LaValley MP, Duran J, Braun J, Felson DT. Comparison of oral versus parenteral methotrexate in the treatment of rheumatoid arthritis: A meta-analysis. PLoS One. 2019;14(9):e0221823. doi: 10.1371/journal.pone.0221823

53. Otón T, Carmona L, Loza E, Rosario MP, Andreu JL. Use of parenteral methotrexate in rheumatic diseases: A systematic review. Reumatol Clin (Engl Ed). 2022;18(4):207-226. doi: 10.1016/j.reumae. 2020.11.006

54. Gaujoux-Viala C, Hudry C, Zinovieva E, Herman-Demars H, Flipo RM. MTX optimization or adding bDMARD equally improve disease activity in rheumatoid arthritis: Results from the prospective study STRATEGE. Rheumatology (Oxford). 2021;61(1):270-280. doi: 10.1093/rheumatology/keab274

55. Li CKH, Baker K, Jones T, Coulson E, Roberts A, Birrell F. Safety and tolerability of subcutaneous methotrexate in routine clinical practice. Arthritis Care Res (Hoboken). 2021;73(9):1306-1311. doi: 10.1002/acr.24334

56. Каратеев ДЕ, Лучихина ЕЛ, Демидова НВ, Гриднева ГС, Лукина ГВ, Канонирова МА, и др. Применение подкожной формы метотрексата для лечения больных активным ревматоидным артритом (исследование РЕМАРКА). Научно-практическая ревматология. 2016;54(2):138-144. [Karateev DE, Luchikhina EL, Demidova NV, Gridneva GS, Lukina GV,Kanonirova MA, et al. Use of subcutaneous methotrexate for the treatment of patients with active rheumatoid arthritis: The REMARCA trial. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2016;54(2):138-144 (In Russ.)]. doi: 10.14412/1995-4484-2016-138-144

57. Муравьев ЮВ, Гриднева ГИ, Каратеев ДЕ, Лучихина ЕЛ. Безопасность применения метотрексата в форме раствора для подкожных инъекций у больных ревматоидным артритом. Научно-практическая ревматология. 2015;53(4):371-374 [Muravyev YuV, Gridneva GI, Karateev DE, Luchichina EL. Safety of using methotrexate solution for subcutaneous injections in patients with rheumatoid arthritis. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2015;53(4):371-374 (In Russ.)]. doi: 10.14412/1995-4484-2015-371-374

58. Schiff MH, Jaffe JS, Freundlich B. Head-to-head, randomized, crossover study of oral versus subcutaneous methotrexate in patients with rheumatoid arthritis: drug-exposure limitations of oral methotrexate at dose ≥15 mg may be overcome with subcuta neous administration. Ann Rheum Dis. 2014;73(8):1549-1551. doi: 10.1136/annrheumdis-2014-205228

59. Hebing RC, Lin M, Bulatovic Calasan M, Muller IB, Mahmoud S, Heil S, et al. Pharmacokinetics of oral and subcutaneous methotrexate in red and white blood cells in patients with early rheumatoid arthritis: The methotrexate monitoring trial. Ann Rheum Dis. 2022 Dec 21:ard-2022-223398. doi: 10.1136/ard-2022-223398

60. Artacho A, Isaac S, Nayak R, Flor-Duro A, Alexander M, Koo I, et al. The pretreatment gut microbiome is associated with lack of response to methotrexate in new-onset rheumatoid arthritis. Arthritis Rheumatol. 2021;73(6):931-942. doi: 10.1002/art.41622

61. Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, van Zeben D, Kerstens PJ, Hazes JM, et al. Comparison of treatment strategies in early rheumatoid arthritis: A randomized trial. Ann Intern Med. 2007;146(6):406-415. doi: 10.7326/0003-4819-146-6-200703200-00005

62. Nam JL, Villeneuve E, Hensor EM, Conaghan PG, Keen HI, Buch MH, et al. Remission induction comparing infliximab and high-dose intravenous steroid, followed by treat-to-target: A double-blind, randomised, controlled trial in new-onset, treatment-naive, rheumatoid arthritis (the IDEA study). Ann Rheum Dis. 2014;73(1):75-85. doi: 10.1136/annrheumdis-2013-203440

63. Emery P, Bingham CO 3rd, Burmester GR, Bykerk VP, Furst DE, Mariette X, et al. Certolizumab pegol in combination with doseoptimised methotrexate in DMARD-naïve patients with early, active rheumatoid arthritis with poor prognostic factors: 1-year results from C-EARLY, a randomised, double-blind, placebo-controlled phase III study. Ann Rheum Dis. 2017;76(1):96-104. doi: 10.1136/annrheumdis-2015-209057

64. Verschueren P, De Cock D, Corluy L, Joos R, Langenaken C, Taelman V, et al. Methotrexate in combination with other DMARDs is not superior to methotrexate alone for remission induction with moderate-to-high-dose glucocorticoid bridging in early rheumatoid arthritis after 16 weeks of treatment: The Care-RA trial. Ann Rheum Dis. 2015;74(1):27-34. doi: 10.1136/annrheumdis-2014-205489

65. Verschueren P, De Cock D, Corluy L, Joos R, Langenaken C, Taelman V, et al. Effectiveness of methotrexate with step-down glucocorticoid remission induction (COBRA Slim) versus other intensive treatment strategies for early rheumatoid arthritis in a treat-to-target approach: 1-year results of CareRA, a randomised pragmatic open-label superiority trial. Ann Rheum Dis. 2017;76(3):511-520. doi: 10.1136/annrheumdis-2016-209212

66. Stouten V, Westhovens R, Pazmino S, De Cock D, Van der Elst K, Joly J, et al.; CareRA study group. Effectiveness of different combinations of DMARDs and glucocorticoid bridging in early rheumatoid arthritis: Two-year results of CareRA. Rheumatology (Oxford). 2019;58(12):2284-2294. doi: 10.1093/rheumatology/kez213

67. Emery P, Horton S, Dumitru RB, Naraghi K, van der Heijde D, Wakefield RJ, et al. Pragmatic randomised controlled trial of very early etanercept and MTX versus MTX with delayed etanercept in RA: The VEDERA trial. Ann Rheum Dis. 2020;79(4):464-471. doi: 10.1136/annrheumdis-2019-216539

68. Hetland ML, Haavardsholm EA, Rudin A, Nordström D, Nurmohamed M, Gudbjornsson B, et al.; NORD-STAR study group. Active conventional treatment and three different biological treatments in early rheumatoid arthritis: Phase IV investigator initiated, randomised, observer blinded clinical trial. BMJ. 2020;371:m4328. doi: 10.1136/bmj.m4328

69. Emery P, Breedveld FC, Hall S, Durez P, Chang DJ, Robertson D, et al. Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): A randomised, double-blind, parallel treatment trial. Lancet. 2008;372(9636):375-382. doi: 10.1016/S0140-6736(08)61000-4

70. Soubrier M, Puéchal X, Sibilia J, Mariette X, Meyer O, Combe B, et al. Evaluation of two strategies (initial methotrexate monotherapy vs its combination with adalimumab) in management of early active rheumatoid arthritis: Data from the GUEPARD trial. Rheumatology (Oxford). 2009;48(11):1429-1434. doi: 10.1093/rheumatology/kep261

71. Moreland LW, O’Dell JR, Paulus HE, Curtis JR, Bathon JM, St Clair EW, et al.; TEAR Investigators. A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: The treatment of Early Aggressive Rheumatoid Arthritis Trial. Arthritis Rheum. 2012;64(9):2824-2835. doi: 10.1002/art.34498

72. Kavanaugh A, van Vollenhoven RF, Fleischmann R, Emery P, Sainsbury I, Florentinus S, et al. Testing treat-to-target outcomes with initial methotrexate monotherapy compared with initial tumour necrosis factor inhibitor (adalimumab) plus methotrexate in early rheumatoid arthritis. Ann Rheum Dis. 2018;77(2):289-292. doi: 10.1136/annrheumdis-2017-211871

73. Stouten V, Joly J, De Cock D. Sustained effectiveness after remission induction with methotrexate and step-down glucocorticoids in patients with early rheumatoid arthritis following a treat-to-target strategy after 2 years. Arthritis and Rheumatology Conference: American College of Rheumatology/Association of Rheumatology Health Professionals Annual Scientific Meeting, ACR/ARHP 2017. 2017.

74. Register KA, Cannella AC, Mikuls TR. Leflunomide, sulfasalazine and hydroxychloroquine for rheumatoid arthritis: efficacious but poorly tolerated. Arthritis and Rheumatology Conference: American College of Rheumatology/Association of Rheumatology Health Professionals Annual Scientific Meeting, ACR/ARHP 2016. 2016.

75. O’Dell JR, Mikuls TR, Taylor TH, Ahluwalia V, Brophy M, Warren SR, et al.; CSP 551 RACAT Investigators. Therapies for active rheumatoid arthritis after methotrexate failure. N Engl J Med. 2013;369(4):307-318. doi: 10.1056/NEJMoa1303006

76. Weinblatt ME, Schiff M, Valente R, van der Heijde D, Citera G, Zhao C, et al. Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: Findings of a phase IIIb, multinational, prospective, randomized study. Arthritis Rheum. 2013;65(1):28-38. doi: 10.1002/art.37711

77. Schiff M, Weinblatt ME, Valente R, van der Heijde D, Citera G, Elegbe A, et al. Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: Two-year efficacy and safety findings from AMPLE trial. Ann Rheum Dis. 2014;73(1):86-94. doi: 10.1136/annrheumdis-2013-203843

78. Smolen JS, Burmester GR, Combe B, Curtis JR, Hall S, Haraoui B, et al. Head-to-head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2-year efficacy and safety results from the randomised EXXELERATE study. Lancet. 2016;388(10061):2763-2774. doi: 10.1016/S0140-6736(16)31651-8

79. Boers M, Hartman L, Opris-Belinski D, Bos R, Kok MR, Da Silva JA, et al.; GLORIA Trial consortium. Low dose, add-on prednisolone in patients with rheumatoid arthritis aged 65+: The pragmatic randomised, double-blind placebo-controlled GLORIA trial. Ann Rheum Dis. 2022;81(7):925-936. doi: 10.1136/annrheumdis-2021-221957

80. Насонов ЕЛ. Новые рекомендации по лечению ревматоидного артрита (EULAR, 2013): место глюкокортикоидов. Научно-практическая ревматология. 2015;53(3):238-250. [Nasonov EL. New guidelines for the management of rheumatoid arthritis (EULAR, 2013): The place of glucocorticoids. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2015;53(3):238-250 (In Russ.)] doi: 10.14412/1995-4484-2015-238-250

81. Emery P, Sebba A, Huizinga TWJ. Biologic and oral diseasemodifying antirheumatic drug monotherapy in rheumatoid arthritis. Ann Rheum Dis. 2013;72(12):1897-1904. doi: 10.1136/annrheumdis-2013-203485

82. Emery P, Pope JE, Kruger K, Lippe R, DeMasi R, Lula S, et al. Efficacy of monotherapy with biologics and JAK inhibitors for the treatment of rheumatoid arthritis: A systematic review. Adv Ther. 2018;35(10):1535-1563. doi: 10.1007/s12325-018-0757-2

83. Насонов ЕЛ, Авдеева АС, Лила АМ. Эффективность и безопасность тофацитиниба при иммуновоспалительных ревматических заболеваниях (часть I). Научно-практическая ревматология. 2020;58(1):62-79. [Nasonov EL, Avdeeva AS, Lila AM. Efficacy and safety of tofacitinib for immune-mediated inflammatory rheumatic diseases (Part I). Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2020;58(1):62-79 (In Russ.)]. doi: 10.14412/1995-4484-2020-62-79

84. Насонов ЕЛ, Лила АМ. Барицитиниб: новые возможности фармакотерапии ревматоидного артрита и других иммуновоспалительных ревматических заболеваний. Научно-практическая ревматология. 2020;58(3):304-316. [Nasonov EL, Lila AM. Baricitinib: New pharmacotherapy options for rheumatoid arthritis and other immune-mediated inflammatory rheumatic diseases. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2020;58(3):304-316 (In Russ.)] doi: 10.14412/1995-4484-2020-304-316

85. Насонов ЕЛ, Лила АМ. Перспективы применения упадацитиниба при ревматоидном артрите и других иммуновоспалительных ревматических заболеваниях. Научно-практическая ревматология. 2020;58(5):532-543. [Nasonov EL, Lila AM. The progress of rheumatology in the 21st century potential uses of upadacitinib in rheumatoid arthritis and other inflammatory rheumatic diseases. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2020;58(5):532-543 (In Russ.)]. doi: 10.47360/1995-4484-2020-532-543

86. Durán J, Bockorny M, Dalal D, LaValley M, Felson DT. Methotrexate dosage as a source of bias in biological trials in rheumatoid arthritis: A systematic review. Ann Rheum Dis. 2016;75(9):1595-1598. doi: 10.1136/annrheumdis-2016-209383

87. Tarp S, Jørgensen TS, Furst DE, Dossing A, Taylor PC, Choy EH, et al. Added value of combining methotrexate with a biological agent compared to biological monotherapy in rheumatoid arthritis patients: A systematic review and metaanalysis of randomised trials. Semin Arthritis Rheum. 2019;48(6): 958-966. doi: 10.1016/j.semarthrit.2018.10.002

88. Delpech C, Laborne FX, Hilliquin P. Comparison of biological agent monotherapy and associations including disease-modifying antirheumatic drugs for rheumatoid arthritis: Literature review and meta-analysis of randomized trials. J Clin Med. 2022;12(1): 286. doi: 10.3390/jcm12010286

89. Liu L, Yan YD, Shi FH, Lin HW, Gu ZC, Li J. Comparative efficacy and safety of JAK inhibitors as monotherapy and in combination with methotrexate in patients with active rheumatoid arthritis: A systematic review and meta-analysis. Front Immunol. 2022;13:977265. doi: 10.3389/fimmu.2022.977265

90. Gehin JE, Goll GL, Brun MK, Jani M, Bolstad N, Syversen SW. Assessing immunogenicity of biologic drugs in inflammatory joint diseases: Progress towards personalized medicine. BioDrugs. 2022;36(6):731-748. doi: 10.1007/s40259-022-00559-1

91. Krieckaert CL, van Tubergen A, Gehin JE, Hernández-Breijo B, Le Mélédo G, Balsa A, et al. EULAR points to consider for therapeutic drug monitoring of biopharmaceuticals in inflammatory rheumatic and musculoskeletal diseases. Ann Rheum Dis. 2023;82(1):65-73. doi: 10.1136/annrheumdis-2022-222155

92. Burmester GR, Kivitz AJ, Kupper H, Arulmani U, Florentinus S, Goss SL, et al. Efficacy and safety of ascending methotrexate dose in combination with adalimumab: The randomised CONCERTO trial. Ann Rheum Dis. 2015;74(6):1037-1044. doi: 10.1136/annrheumdis-2013-204769

93. Tamai H, Ikeda K, Miyamoto T, Taguchi H, Kuo C-F, Shin K, et al. Reduced versus maximum tolerated methotrexate dose concomitant with adalimumab in patients with rheumatoid arthritis (MIRACLE): A randomised, open-label, non-inferiority trial. Lancet Rheumatol. 2023;5:e215-e224. doi: 10.1016/s2665-9913(23)00070-x

94. Kaeley GS, Evangelisto AM, Nishio MJ, Goss SL, Liu S, Kalabic J, et al. Methotrexate dosage reduction upon adalimumab initiation: Clinical and ultrasonographic outcomes from the randomized noninferiority MUSICA trial. J Rheumatol. 2016;43(8):1480-1489. doi: 10.3899/jrheum.151009

95. Strangfeld A, Hierse F, Kekow J, von Hinueber U, Tony HP, Dockhorn R, et al. Comparative effectiveness of tumour necrosis factor alpha inhibitors in combination with either methotrexate or leflunomide. Ann Rheum Dis. 2009;68(12):1856-1862. doi: 10.1136/ard.2008.098467

96. Alten R, Burkhardt H, Feist E, Krüger K, Rech J, Rubbert-Roth A, et al. Abatacept used in combination with non-methotrexate disease-modifying antirheumatic drugs: A descriptive analysis of data from interventional trials and the real-world setting. Arthritis Res Ther. 2018;20(1):1. doi: 10.1186/s13075-017-1488-5

97. Narváez J, Díaz-Torné C, Magallares B, Hernández MV, Reina D, Corominas H, et al. Comparative effectiveness of tocilizumab with either methotrexate or leflunomide in the treatment of rheumatoid arthritis. PLoS One. 2015;10(4):e0123392. doi: 10.1371/journal.pone.0123392

98. Aaltonen KJ, Joensuu JT, Pirilä L, Kauppi M, Uutela T, Varjolahti-Lehtinen T, et al. Drug survival on tumour necrosis factor inhibitors in patients with rheumatoid arthritis in Finland. Scand J Rheumatol. 2017;46(5):359-363. doi: 10.1080/03009742. 2016.1234641

99. Maassen JM, van Ouwerkerk L, Allaart CF. Tapering of diseasemodifying antirheumatic drugs: An overview for daily practice. Lancet Rheumatol. 2021;3:659-670.

100. Meng CF, Rajesh DA, Jannat-Khah DP, Jivanelli B, Bykerk VP. Can patients with controlled rheumatoid arthritis taper methotrexate from targeted therapy and sustain remission? A systematic review and metaanalysis. J Rheumatol. 2023;50(1):36-47. doi: 10.3899/jrheum.220152

101. Uhrenholt L, Christensen R, Dinesen W, Liboriussen C, Andersen S, Dreyer L, et al. Tapering and withdrawal of biologics or targeted synthetic disease-modifying antirheumatic drugs in patients with inflammatory arthritis: A systematic review and meta-analyses of randomised trials. Arthritis Rheumatol. 2021;73(Suppl 9). URL: https://acrabstracts.org/abstract/tapering-and-withdrawalof-biologics-or-targeted-synthetic-disease-modifying-antirheumatic-drugs-in-patients-with-inflammatory-arthritis-a-systematic-review-and-meta-analyses-of-randomised-trials/(Accessed: 13th May 2023).

102. Sherbini AA, Sharma SD, Gwinnutt JM, Hyrich KL, Verstappen SMM. Prevalence and predictors of adverse events with methotrexate mono-and combination-therapy for rheumatoid arthritis: A systematic review. Rheumatology (Oxford). 2021;60(9):4001-4017. doi: 10.1093/rheumatology/keab304

103. Sherbini AA, Gwinnutt JM, Hyrich KL; RAMS Co-Investigators; Verstappen SMM. Rates and predictors of methotrexate-related adverse events in patients with early rheumatoid arthritis: Results from a nationwide UK study. Rheumatology (Oxford). 2022;61(10):3930-3938. doi: 10.1093/rheumatology/keab917

104. Verstappen SM, Bakker MF, Heurkens AH, van der Veen MJ, Kruize AA, Geurts MA, May; Utrecht Rheumatoid Arthritis Cohort Study Group. Adverse events and factors associated with toxicity in patients with early rheumatoid arthritis treated with methotrexate tight control therapy: the CAMERA study. Ann Rheum Dis. 2010;69(6):1044-1048. doi: 10.1136/ard.2008.106617

105. de Rotte MC, den Boer E, de Jong PH, Pluijm SM, Ćalasan MB, Weel AE, May methotrexate polyglutamates in erythrocytes are associated with lower disease activity in patients with rheumatoid arthritis. Ann Rheum Dis. 2015;74(2):408-414. doi: 10.1136/annrheumdis-2013-203725

106. Bluett J, Sergeant JC, MacGregor AJ, Chipping JR, Marshall T, Symmons DPM, Risk factors for oral methotrexate failure in patients with inflammatory polyarthritis: Results from a UK prospective cohort study. Arthritis Res Ther. 2018;20(1):50. doi: 10.1186/s13075-018-1544-9

107. Hider SL, Silman AJ, Thomson W, Lunt M, Bunn D, Symmons DP. Can clinical factors at presentation be used to predict outcome of treatment with methotrexate in patients with early inflammatory polyarthritis? Ann Rheum Dis. 2009;68(1):57-62. doi: 10.1136/ard.2008.088237

108. Dirven L, Klarenbeek NB, van den Broek M, van Groenendael JH, de Sonnaville PB, Kerstens PJ, May Risk of alanine transferase (ALT) elevation in patients with rheumatoid arthritis treated with methotrexate in a DAS-steered strategy. Clin Rheumatol. 2013;32(5):585-590. doi: 10.1007/s10067-012-2136-8

109. Solomon DH, Glynn RJ, Karlson EW, Lu F, Corrigan C, Colls J, May Adverse effects of low-dose methotrexate: A randomized trial. Ann Intern Med. 2020;172(6):369-380. doi: 10.7326/M19-3369

110. Mori S, Arima N, Ito M, Fujiyama S, Kamo Y, Ueki Y. Nonalcoholic steatohepatitis-like pattern in liver biopsy of rheumatoid arthritis patients with persistent transaminitis during low-dose methotrexate treatment. PLoS One. 2018;13(8):e0203084. doi: 10.1371/journal.pone.0203084

111. Onda K, Honma T, Masuyama K. Methotrexate-related adverse events and impact of concomitant treatment with folic acid and tumor necrosis factor-alpha inhibitors: An assessment using the FDA adverse event reporting system. Front Pharmacol. 2023;14:1030832. doi: 10.3389/fphar.2023.1030832

112. Shea B, Swinden MV, Ghogomu ET, Ortiz Z, Katchamart W, Rader T, et al. Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis. J Rheumatol. 2014;41(6):1049-1060. doi: 10.3899/jrheum.130738

113. Di Martino V, Verhoeven DW, Verhoeven F, Aubin F, Avouac J, Vuitton L, et al. Busting the myth of methotrexate chronic hepatotoxicity. Nat Rev Rheumatol. 2023;19(2):96-110. doi: 10.1038/s41584-022-00883-4

114. Zamani M, Alizadeh-Tabari S, Chitkara P, Singh S, Loomba R. Prevalence of nonalcoholic fatty liver disease in patients with rheumatoid arthritis: A systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2023 5:S1542-3565(23)00164-7. doi: 10.1016/j.cgh.2023.02.021

115. Conway R, Low C, Coughlan RJ, O’Donnell MJ, Carey JJ. Risk of liver injury among methotrexate users: A meta-analysis of randomised controlled trials. Semin Arthritis Rheum. 2015;45(2):156-162. doi: 10.1016/j.semarthrit.2015.05.003

116. Cheema HI, Haselow D, Dranoff JA. Review of existing evidence demonstrates that methotrexate does not cause liver fibrosis. J Investig Med. 2022;70(7):1452-1460. doi: 10.1136/jim-2021-002206

117. Atallah E, Grove JI, Crooks C, Burden-Teh E, Abhishek A, Moreea S, et al. Risk of liver fibrosis associated with long-term methotrexate therapy may be overestimated. J Hepatol. 2023;78(5):989-997. doi: 10.1016/j.jhep.2022.12.034

118. Conforti A, Di Cola I, Pavlych V, Ruscitti P, Berardicurti O, Ursini F, et al. Beyond the joints, the extra-articular manifestations in rheumatoid arthritis. Autoimmun Rev. 2021;20(2):102735. doi: 10.1016/j.autrev.2020.102735

119. Wu D, Luo Y, Li T, Zhao X, Lv T, Fang G, et al. Systemic complications of rheumatoid arthritis: Focus on pathogenesis and treatment. Front Immunol. 2022;13:1051082. doi: 10.3389/fimmu.2022.1051082

120. Taylor PC, Atzeni F, Balsa A, Gossec L, Müller-Ladner U, Pope J. The key comorbidities in patients with rheumatoid arthritis: A narrative review. J Clin Med. 2021;10(3):509. doi: 10.3390/jcm10030509

121. Yu KH, Chen HH, Cheng TT, Jan YJ, Weng MY, Lin YJ, et al. Consensus recommendations on managing the selected comorbidities including cardiovascular disease, osteoporosis, and interstitial lung disease in rheumatoid arthritis. Medicine (Baltimore). 2022;101(1):e28501. doi: 10.1097/MD.0000000000028501

122. Ruscitti P, Di Muzio C, Conforti A, Di Cola I, Pavlych V, Navarini L, et al. Cardiometabolic multimorbidity may identify a more severe subset of rheumatoid arthritis, results from a “reallife” study. Medicine (Baltimore). 2023;102(14):e33362. doi: 10.1097/MD.0000000000033362

123. DeMizio DJ, Geraldino-Pardilla LB. Autoimmunity and inflammation link to cardiovascular disease risk in rheumatoid arthritis. Rheumatol Ther. 2020;7(1):19-33. doi: 10.1007/s40744-019-00189-0

124. Skeoch S, Bruce IN. Atherosclerosis in rheumatoid arthritis: is it all about inflammation? Nat Rev Rheumatol. 2015;11(7):390-400. doi: 10.1038/nrrheum.2015.40

125. McDermott GC, Doyle TJ, Sparks JA. Interstitial lung disease throughout the rheumatoid arthritis disease course. Curr Opin Rheumatol. 2021;33(3):284-291. doi: 10.1097/BOR.0000000000000787

126. Насонов ЕЛ, Ананьева ЛП, Авдеев СН. Интерстициальные заболевания легких при ревматоидном артрите: мультидисциплинарная проблема ревматологии и пульмонологии. Научно-практическая ревматология. 2022;60(6):517-534. [Nasonov EL, Ananyeva LP, Avdeev SN. Interstitial lung disease in rheumatoid arthritis: A multidisciplinary problem in rheumatology and pulmonology. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2022;60(6):517-534 (In Russ.)] doi: 10.47360/1995-4484-2022-1

127. Попкова ТВ, Герасимова ЕВ, Новикова ДС, Насонов ЕЛ. Метотрексат и риск сердечно-сосудистых осложнений при ревматоидном артрите. Научно-практическая ревматология. 2012;50(6):70-79. [Popkova TV, Gerasimova EV, Novikova DS, Nasonov EL. Methotrexate and cardiovascular risk in rheumatoid arthritis. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2012;50(6):70-79 (In Russ.)]. doi: 10.14412/1995-4484-2012-1297

128. Micha R, Imamura F, Wyler von Ballmoos M, Solomon DH, Hernán MA, Ridker PM, et al. Systematic review and metaanaly sis of methotrexate use and risk of cardiovascular disease. Am J Cardiol. 2011;108(9):1362-1370. doi: 10.1016/j.amjcard. 2011.06.054

129. Roubille C, Richer V, Starnino T, McCourt C, McFarlane A, Fleming P, et al. The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: A systematic review and meta-analysis. Ann Rheum Dis. 2015;74(3):480-489. doi: 10.1136/annrheumdis-2014-206624

130. Widdifield J, Abrahamowicz M, Paterson JM, Huang A, Thorne JC, Pope JE, et al. Associations between methotrexate use and the risk of cardiovascular events in patients with elderlyonset rheumatoid arthritis. J Rheumatol. 2019;46(5):467-474. doi: 10.3899/jrheum.180427

131. Sun KJ, Liu LL, Hu JH, Chen YY, Xu DY. Methotrexate can prevent cardiovascular events in patients with rheumatoid arthritis: An updated meta-analysis. Medicine (Baltimore). 2021;100(7):e24579. doi: 10.1097/MD.0000000000024579

132. Solomon DH, Giles JT, Liao KP, Ridker PM, Rist PM, Glynn RJ, et al.; TARGET Trial Consortium. Reducing cardiovascular risk with immunomodulators: A randomised active comparator trial among patients with rheumatoid arthritis. Ann Rheum Dis. 2023;82(3):324-330. doi: 10.1136/ard-2022-223302

133. Mangoni AA, Zinellu A, Sotgia S, Carru C, Erre GL. Methotrexate and cardiovascular protection: Current evidence and future directions. Clinical Medicine Insights: Therapeutics. 2017;9. doi: 10.1177/1179559X17741289

134. Ytterberg SR, Bhatt DL, Mikuls TR, Koch GG, Fleischmann R, Rivas JL, et al.; ORAL Surveillance Investigators. Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. N Engl J Med. 2022;386(4):316-326. doi: 10.1056/NEJMoa2109927

135. Kremer JM, Bingham CO 3rd, Cappelli LC, Greenberg JD, Madsen AM, Geier J, et al. Postapproval comparative safety study of tofacitinib and biological disease-modifying antirheumatic drugs: 5-year results from a United States-based rheumatoid arthritis registry. ACR Open Rheumatol. 2021;3(3):173-184. doi: 10.1002/acr2.11232

136. Conway R, Low C, Coughlan RJ, O’Donnell MJ, Carey JJ. Methotrexate and lung disease in rheumatoid arthritis: A metaanalysis of randomized controlled trials. Arthritis Rheumatol. 2014;66(4):803-812. doi: 10.1002/art.38322

137. Conway R, Low C, Coughlan RJ, O’Donnell MJ, Carey JJ. Leflunomide use and risk of lung disease in rheumatoid arthritis: A systematic literature review and metaanalysis of randomized controlled trials. J Rheumatol. 2016;43(5):855-860. doi: 10.3899/jrheum.150674

138. Juge PA, Lee JS, Lau J, Kawano-Dourado L, Rojas Serrano J, Sebastiani M, et al. Methotrexate and rheumatoid arthritis associated interstitial lung disease. Eur Respir J. 2021;57(2):2000337. doi: 10.1183/13993003.00337-2020

139. Robles-Pérez A, Luburich P, Bolivar S, Dorca J, Nolla JM, Molina-Molina M, et al. A prospective study of lung disease in a cohort of early rheumatoid arthritis patients. Sci Rep. 2020;10(1):15640. doi: 10.1038/s41598-020-72768-z

140. Ibfelt EH, Jacobsen RK, Kopp TI, Cordtz RL, Jakobsen AS, Seersholm N, et al. Methotrexate and risk of interstitial lung disease and respiratory failure in rheumatoid arthritis: A nationwide population-based study. Rheumatology (Oxford). 2021;60(1):346-352. doi: 10.1093/rheumatology/keaa327

141. Li L, Liu R, Zhang Y, Zhou J, Li Y, Xu Y, et al. A retrospective study on the predictive implications of clinical characteristics and therapeutic management in patients with rheumatoid arthritis-associated interstitial lung disease. Clin Rheumatol. 2020;39(5):1457-1470. doi: 10.1007/s10067-019-04846-1

142. Kiely P, Busby AD, Nikiphorou E, Sullivan K, Walsh DA, Creamer P, et al. Is incident rheumatoid arthritis interstitial lung disease associated with methotrexate treatment? Results from a multivariate analysis in the ERAS and ERAN inception cohorts. BMJ Open. 2019;9(5):e028466. doi: 10.1136/bmjopen-2018-028466

143. Rojas-Serrano J, González-Velásquez E, Mejía M, Sánchez-Rodríguez A, Carrillo G. Interstitial lung disease related to rheumatoid arthritis: Evolution after treatment. Reumatol Clin. 2012;8(2):68-71. doi: 10.1016/j.reuma.2011.12.008

144. Rojas-Serrano J, Herrera-Bringas D, Pérez-Román DI, Pérez-Dorame R, Mateos-Toledo H, Mejía M. Rheumatoid arthritis-related interstitial lung disease (RA-ILD): Methotrexate and the severity of lung disease are associated to prognosis. Clin Rheumatol. 2017;36(7):1493-1500. doi: 10.1007/s10067-017-3707-5

145. Detorakis EE, Magkanas E, Lasithiotaki I, Sidiropoulos P, Boumpas DT, Gourtsoyiannis N, et al. Evolution of imaging findings, laboratory and functional parameters in rheumatoid arthritis patients after one year of treatment with anti-TNF-α agents. Clin Exp Rheumatol. 2017;35(1):43-52

146. Dixon WG, Hyrich KL, Watson KD, Lunt M; BSRBR Control Centre Consortium, Symmons DP; British Society for Rheumatology Biologics Register. Influence of anti-TNF therapy on mortality in patients with rheumatoid arthritis-associated interstitial lung disease: Results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis. 2010;69(6):1086-1091. doi: 10.1136/ard.2009.120626

147. Fragoulis GE, Nikiphorou E, Larsen J, Korsten P, Conway R. Methotrexate-associated pneumonitis and rheumatoid arthritisinterstitial lung disease: Current concepts for the diagnosis and treatment. Front Med (Lausanne). 2019;6:238. doi: 10.3389/fmed.2019.00238

148. Conway R, Nikiphorou E. Treating interstitial lung disease in rheumatoid arthritis – The embers of hope. Rheumatology (Oxford). 2020;59(12):3589-3590. doi: 10.1093/rheumatology/keaa516

149. Sparks JA, Dellaripa PF, Glynn RJ, Paynter NP, Xu C, Ridker PM, et al. Pulmonary adverse events in patients receiving lowdose methotrexate in the randomized, double-blind, placebocontrolled cardiovascular inflammation reduction trial. Arthritis Rheumatol. 2020;72(12):2065-2071. doi: 10.1002/art.41452

150. Albrecht K, Luque Ramos A, Hoffmann F, Redeker I, Zink A. High prevalence of diabetes in patients with rheumatoid arthritis: Results from a questionnaire survey linked to claims data. Rheumatology (Oxford). 2018;57(2):329-336. doi: 10.1093/rheumatology/kex414

151. Cacciapaglia F, Spinelli FR, Bartoloni E, Bugatti S, Erre GL, Fornaro M, et al. Clinical features of diabetes mellitus on rheumatoid arthritis: Data from the Cardiovascular Obesity and Rheumatic DISease (CORDIS) study group. J Clin Med. 2023;12(6): 2148. doi: 10.3390/jcm12062148

152. Tian Z, Mclaughlin J, Verma A, Chinoy H, Heald AH. The relationship between rheumatoid arthritis and diabetes mellitus: A systematic review and meta-analysis. Cardiovasc Endocrinol Metab. 2021;10(2):125-131. doi: 10.1097/XCE.0000000000000244

153. Di Muzio C, Cipriani P, Ruscitti P. Rheumatoid arthritis treatment options and type 2 diabetes: Unravelling the association. BioDrugs. 2022;36(6):673-685. doi: 10.1007/s40259-022-00561-7

154. Nam SH, Kim M, Kim YJ, Ahn SM, Hong S, Lee CK, et al. Risk of new-onset diabetes mellitus associated with antirheumatic drugs in patients with rheumatoid arthritis: A nationwide population study. J Clin Med. 2022;11(8):2109. doi: 10.3390/jcm11082109

155. Baghdadi LR. Effect of methotrexate use on the development of type 2 diabetes in rheumatoid arthritis patients: A systematic review and meta-analysis. PLoS One. 2020;15(7):e0235637. doi: 10.1371/journal.pone.0235637

156. Sparks JA, Vanni KMM, Sparks MA, Xu C, Santacroce LM, Glynn RJ, et al. Effect of low-dose methotrexate on eGFR and kidney adverse events: A randomized clinical trial. J Am Soc Nephrol. 2021;32(12):3197-3207. doi: 10.1681/ASN.2021050598

157. Asai S, Kojima T, Oguchi T, Kaneko A, Hirano Y, Yabe Y, et al. Effects of concomitant methotrexate on large joint replacement in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors: A multicenter retrospective cohort study in Japan. Arthritis Care Res (Hoboken). 2015;67(10):1363-1370. doi: 10.1002/acr.22596

158. Asai S, Takahashi N, Funahashi K, Yoshioka Y, Takemoto T, Terabe K, et al. Concomitant methotrexate protects against total knee arthroplasty in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors. J Rheumatol. 2015;42(12):2255-2260. doi: 10.3899/jrheum.150410

159. Xu C, Yong MY, Koh ET, Dalan R, Leong KP; and the TTSH Rheumatoid Arthritis Study Group. The impact of diabetes mellitus on treatment and outcomes of rheumatoid arthritis at 5-year follow-up: Results from a multi-ethnic Asian cohort. Rheumatol Adv Pract. 2021;5(3):rkab077. doi: 10.1093/rap/rkab077

160. Насонов ЕЛ, Лила АМ, Мазуров ВИ, Белов БС, Каратеев АЕ, Дубинина ТВ, et al. Коронавирусная болезнь 2019 (COVID-19) и иммуновоспалительные ревматические заболевания. Рекомендации Общероссийской общественной организации «Ассоциация ревматологов России». Научно-практическая ревматология. 2021;59(3):239-254. [Nasonov EL, Lila AM, Mazurov VI, Belov BS, Karateev AE, Dubinina TV, et al. Coronavirus disease 2019 (COVID-19) and immune-mediated rheumatic diseases. Recommendations of the Association of Rheumatologists of Russia. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2021;59(3):239-254 (In Russ.)]. doi: 10.47360/1995-4484-2021-239-254

161. Ganjei Z, Faraji Dana H, Ebrahimi-Dehkordi S, Alidoust F, Bahmani K. Methotrexate as a safe immunosuppressive agent during the COVID-19 pandemic. Int Immunopharmacol. 2021;101(Pt B):108324. doi: 10.1016/j.intimp.2021.108324

162. Schälter F, Dürholz K, Bucci L, Burmester G, Caporali R, Figuereido C, et al. Does methotrexate influence COVID-19 infection? Case series and mechanistic data. Arthritis Res Ther. 2021;23(1):166. doi: 10.1186/s13075-021-02464-4

163. Xu J, Xiao L, Zhu J, Qin Q, Fang Y, Zhang JA. Methotrexate use reduces mortality risk in rheumatoid arthritis: A systematic review and meta-analysis of cohort studies. Semin Arthritis Rheum. 2022;55:152031. doi: 10.1016/j.semarthrit.2022.152031